Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.66 |
| ▸ | DRD1 | P21728 | 3/20 | 0.66 |
| ▸ | DRD3 | P35462 | 3/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.66 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.66 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.66 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | HRH1 | P35367 | 1/20 | 0.66 |
| ▸ | HTR2B | P41595 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246058 | 0.90 | KCNH2 (0.71) | CYP2D6OPRM1CHRM2ADRA2ACHRM1 | |
| SCHEMBL3919536 | 0.85 | OPRM1 (0.78) | CYP2D6OPRM1CHRM2ADRA2ACHRM1 | |
| SCHEMBL8186671 | 0.85 | OPRM1 (0.78) | CYP2D6OPRM1CHRM2ADRA2ACHRM1 | |
| SCHEMBL7977689 | 0.85 | OPRM1 (0.78) | CYP2D6OPRM1CHRM2ADRA2ACHRM1 | |
| SCHEMBL8175607 | 0.85 | OPRM1 (0.78) | CYP2D6OPRM1CHRM2ADRA2ACHRM1 | |
| SCHEMBL16448455 | 0.83 | OPRM1 (0.70) | CYP2D6OPRM1CHRM2ADRA2ACHRM1 | |
| SCHEMBL16226967 | 0.82 | CYP2D6 (0.83) | CYP2D6OPRM1CHRM2ADRA2ACHRM1 | |
| SCHEMBL3977325 | 0.80 | OPRM1 (0.66) | CYP2D6OPRM1CHRM2ADRA2ACHRM1 | |
| Hydrochloric Acid SCHEMBL16225962 | 0.80 | CYP2D6 (0.80) | CYP2D6OPRM1CHRM2ADRA2ACHRM1 | |
| SCHEMBL4249531 | 0.79 | OPRM1 (0.59) | CYP2D6OPRM1CHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757590-B1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INST SCI & TECH (KR) | 2009-12-02 | — | — | EP | disclosed |
| US-7544686-B2 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-06-09 | — | — | US | disclosed |
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-03-01 | — | — | US | disclosed |
| EP-1757590-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | Korea Institute of Science and Technology (KR) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | CACNA1I, CACNA1G, CACNA1H | CYP2D6 1325/4885OPRM1 438/4885CHRM2 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.